Explore Cagrilintide + Semaglutide (CagriSema) dosage trends, reconstitution volumes, and vial size patterns from anonymized WPA peptide calculator sessions.
Cagrilintide + Semaglutide, known in clinical development as CagriSema (Novo Nordisk), pairs the long-acting amylin analog cagrilintide with the GLP-1 receptor agonist semaglutide in a single once-weekly co-formulation, studied in the REDEFINE program for obesity and type 2 diabetes. The combination targets two complementary satiety pathways at once. This data shows the dose amounts, vial sizes, and bacteriostatic water volumes researchers most commonly select when reconstituting a Cagrilintide + Semaglutide blend.
34 Cagrilintide + Semaglutide reconstitution calculations have been logged by the WPA community. The most common dose entered is 2.4mg (5 calculations). The median dose across all sessions is 1mg. The most common bacteriostatic water volume is 2mL. The most popular vial size is 10mg (16 sessions). The most common dosing frequency is daily (7x/week) (1 logged protocols), followed by once weekly (1).
World Peptide Association aggregates anonymized peptide calculator data to show real-world dosing trends, reconstitution volumes, and vial size preferences across the research peptide community.
All figures shown are aggregated from anonymized calculator inputs and are provided strictly for independent laboratory research and educational purposes. They are community usage statistics — not dosing recommendations, and not medical advice.